Becton, Dickinson and Company
Every calculator, already run for BDX
Open the full toolkit →You have the numbers on BDX. Get the argument.
A written report on which of these readings actually decide the outcome for Becton, Dickinson and Company, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
14 analysts covering BDXAnalyst Price Target Disagreement for Becton, Dickinson and Company
Wall Street's bull case implies +25% from the current price; the bear case implies -6%. A 30% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for BDX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, h…
BDX — frequently asked
Is BDX a buy right now?
Wall Street's consensus rating on Becton, Dickinson and Company is Buy across 14 analysts, with a mean price target of $195.67 (+8% vs. the current $180.61). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is BDX overvalued?
BDX trades at 31.3x trailing earnings, against a DCF fair value of $639 per share. The current price implies -9% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is BDX's next earnings date?
Becton, Dickinson and Company is next scheduled to report earnings around Nov 5, 2026. A full BDX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Becton, Dickinson and Company?
Analysts covering Becton, Dickinson and Company (BDX) range from a bear-case target of $170.00 to a bull-case high of $225.00, with a mean consensus target of $195.67 across 12 analysts. The spread of $55.00 (30% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Becton, Dickinson and Company against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Becton, Dickinson and Company
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full BDX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Becton, Dickinson and Company, in minutes. 3 free reports included with every account — no credit card required.